We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other genomics ...

Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results tomorrow after the bell. Here’s what investors should know. 10x Genomics beat analysts’ revenue expectations by 3. ...

10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. The company ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

10x Genomics has impressive financials but isn't expected to be profitable until at least 2028, posing significant investment risks. The company's growth heavily relies on its Chromium platform ...

EBT for 10x Genomics decreased from -$19 million in 2017 to -$112 million in 2018, as Operating Expenses grew faster than Revenues. We expect EBT to increase to -$9 million in 2019. How has 10x ...

10x Genomics reported solid year-over-year improvement with its Q4 results. However, the company's 2022 revenue guidance was weaker than expected. The headwinds that 10x faces could be temporary.

10x Genomics’ sequencers allow users to observe gene expression on a cell-by-cell basis, producing a much higher resolution picture of biological processes than previous methods. According to a ...

Sept 14 (Reuters) - Genomics startup Parse Biosciences lost its bid to dismiss a patent-infringement lawsuit brought by rival 10x Genomics (TXG.O), opens new tab and Stanford University on ...

10x Genomics (NASDAQ: TXG), a biotechnology company that designs and manufactures gene sequencing technology, was listed following its IPO in September. While the stock saw some volatility post ...